
In patients with Ewing's sarcoma, a chemotherapy regimen administered every two weeks produces better outcomes than a regimen administered every three weeks, and is not associated with increased toxicity, according to an early release on research to be presented May 30-June 3 at the annual meeting of the American Society of Clinical Oncology in Chicago.